Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 1
1984 1
1985 2
1987 1
1988 2
1990 1
1991 2
1992 4
1993 3
1994 5
1995 1
1996 2
1997 3
1999 5
2000 4
2001 2
2002 4
2003 6
2004 2
2005 4
2006 6
2007 4
2008 5
2009 7
2010 6
2011 11
2012 16
2013 6
2014 7
2015 12
2016 13
2017 9
2018 12
2019 13
2020 12
2021 16
2022 10
2023 6
2024 3
2025 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

210 results

Results by year

Filters applied: . Clear all
Page 1
A Phase 3 Trial of Upadacitinib for Giant-Cell Arteritis.
Blockmans D, Penn SK, Setty AR, Schmidt WA, Rubbert-Roth A, Hauge EM, Keen HI, Ishii T, Khalidi N, Dejaco C, Cid MC, Hellmich B, Liu M, Zhao W, Lagunes I, Romero AB, Wung PK, Merkel PA; SELECT-GCA Study Group. Blockmans D, et al. N Engl J Med. 2025 May 29;392(20):2013-2024. doi: 10.1056/NEJMoa2413449. Epub 2025 Apr 2. N Engl J Med. 2025. PMID: 40174237 Clinical Trial.
Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis.
Baeten D, Sieper J, Braun J, Baraliakos X, Dougados M, Emery P, Deodhar A, Porter B, Martin R, Andersson M, Mpofu S, Richards HB; MEASURE 1 Study Group; MEASURE 2 Study Group. Baeten D, et al. N Engl J Med. 2015 Dec 24;373(26):2534-48. doi: 10.1056/NEJMoa1505066. N Engl J Med. 2015. PMID: 26699169 Free article. Clinical Trial.
Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial.
McInnes IB, Mease PJ, Kirkham B, Kavanaugh A, Ritchlin CT, Rahman P, van der Heijde D, Landewé R, Conaghan PG, Gottlieb AB, Richards H, Pricop L, Ligozio G, Patekar M, Mpofu S; FUTURE 2 Study Group. McInnes IB, et al. Lancet. 2015 Sep 19;386(9999):1137-46. doi: 10.1016/S0140-6736(15)61134-5. Epub 2015 Jun 28. Lancet. 2015. PMID: 26135703 Free article. Clinical Trial.
Erratum zu: Apps in der Rheumatologie.
Strunz PP, Maire ML, Heusinger T, Hammel L, Gernert M, Schwaneck EC, Callhoff J, Portegys J, Schmalzing M, Tony HP, Froehlich M. Strunz PP, et al. Among authors: tony hp. Z Rheumatol. 2021 Dec;80(Suppl 2):76. doi: 10.1007/s00393-021-01121-0. Z Rheumatol. 2021. PMID: 34748079 Free PMC article. German. No abstract available.
Safety and efficacy of secukinumab in patients with giant cell arteritis (TitAIN): a randomised, double-blind, placebo-controlled, phase 2 trial.
Venhoff N, Schmidt WA, Bergner R, Rech J, Unger L, Tony HP, Finzel S, Andreica I, Kofler DM, Weiner SM, Lamprecht P, Schulze-Koops H, App C, Pournara E, Mendelson MH, Sieder C, Maricos M, Thiel J. Venhoff N, et al. Among authors: tony hp. Lancet Rheumatol. 2023 Jun;5(6):e341-e350. doi: 10.1016/S2665-9913(23)00101-7. Lancet Rheumatol. 2023. PMID: 38251601 Clinical Trial.
Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial.
van Laar JM, Farge D, Sont JK, Naraghi K, Marjanovic Z, Larghero J, Schuerwegh AJ, Marijt EW, Vonk MC, Schattenberg AV, Matucci-Cerinic M, Voskuyl AE, van de Loosdrecht AA, Daikeler T, Kötter I, Schmalzing M, Martin T, Lioure B, Weiner SM, Kreuter A, Deligny C, Durand JM, Emery P, Machold KP, Sarrot-Reynauld F, Warnatz K, Adoue DF, Constans J, Tony HP, Del Papa N, Fassas A, Himsel A, Launay D, Lo Monaco A, Philippe P, Quéré I, Rich É, Westhovens R, Griffiths B, Saccardi R, van den Hoogen FH, Fibbe WE, Socié G, Gratwohl A, Tyndall A; EBMT/EULAR Scleroderma Study Group. van Laar JM, et al. Among authors: tony hp. JAMA. 2014 Jun 25;311(24):2490-8. doi: 10.1001/jama.2014.6368. JAMA. 2014. PMID: 25058083 Free article. Clinical Trial.
Risk of major adverse cardiovascular events in patients with rheumatoid arthritis treated with conventional synthetic, biologic and targeted synthetic disease-modifying antirheumatic drugs: observational data from the German RABBIT register.
Meissner Y, Schäfer M, Albrecht K, Kekow J, Zinke S, Tony HP, Strangfeld A. Meissner Y, et al. Among authors: tony hp. RMD Open. 2023 Oct;9(4):e003489. doi: 10.1136/rmdopen-2023-003489. RMD Open. 2023. PMID: 37880180 Free PMC article.
Safety and efficacy of subcutaneous iscalimab (CFZ533) in two distinct populations of patients with Sjögren's disease (TWINSS): week 24 results of a randomised, double-blind, placebo-controlled, phase 2b dose-ranging study.
Fisher BA, Mariette X, Papas A, Grader-Beck T, Bootsma H, Ng WF, van Daele PLA, Finzel S, Noaiseh G, Elgueta S, Hermann J, McCoy SS, Akpek E, Bookman A, Sopala M, Montecchi-Palmer M, Luo WL, Scheurer C, Hueber W; TWINSS study group. Fisher BA, et al. Lancet. 2024 Aug 10;404(10452):540-553. doi: 10.1016/S0140-6736(24)01211-X. Epub 2024 Jul 31. Lancet. 2024. PMID: 39096929 Clinical Trial.
[Hematology meets rheumatology].
Tony HP. Tony HP. Z Rheumatol. 2017 Oct;76(Suppl 2):25. doi: 10.1007/s00393-017-0373-6. Z Rheumatol. 2017. PMID: 28971214 Review. German. No abstract available.
[Cytokines].
Feuchtenberger M, Kneitz C, Tony HP. Feuchtenberger M, et al. Among authors: tony hp. Z Rheumatol. 2007 Jul;66(4):297-8, 300-3. doi: 10.1007/s00393-007-0176-2. Z Rheumatol. 2007. PMID: 17522870 Review. German.
210 results